Fallopian tube cancer Clinical Trials
Recruiting fallopian tube cancer studies with sites across the US, sourced from ClinicalTrials.gov and refreshed daily. Free to join — find one near you below.
Clinical trials study new ways to prevent, detect, or treat fallopian tube cancer. Joining one can give you access to investigational treatments and close monitoring by a specialist research team — at no cost — while helping advance care for others. Below are recruiting fallopian tube cancer studies with sites across the US; use the location tools to find ones near you.
What to expect
- Screening first. The study team reviews your eligibility before anything else — there's no obligation to continue.
- Informed consent. You'll get a full explanation of the study, its potential risks and benefits, and can withdraw at any time.
- No cost to you. Study visits, tests, and the investigational treatment are covered; many studies reimburse travel.
Recruiting fallopian tube cancer trials
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Surgery for Relapsed Ovarian Cancer in Precision
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Study of AVZO-021 in Patients With Advanced Solid Tumors
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer
Using Aspirin to Improve Immunological Features of Ovarian Tumors
A Beta-only IL-2 ImmunoTherapY Study
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Fallopian tube cancer clinical trials — common questions
Are fallopian tube cancer clinical trials free to join?
Yes. Participating in a fallopian tube cancer clinical trial is free — study-related visits, tests, and the investigational treatment are provided at no cost to you. Many studies also reimburse travel and time. You never pay to take part.
Who can join a fallopian tube cancer clinical trial?
Each fallopian tube cancer study sets its own eligibility criteria — typically based on age, medical history, current treatments, and overall health. Every trial listed here shows its criteria, and the study team confirms your eligibility before enrollment. You can review and apply to any that look like a fit.
How do I find a fallopian tube cancer trial near me?
Use the location controls above. We'll show recruiting fallopian tube cancer trials with sites near you, sorted by distance. You can widen the radius or share your exact location for the closest matches.
How many fallopian tube cancer trials are recruiting right now?
We're currently tracking roughly 28 recruiting fallopian tube cancer trials with US sites, sourced from ClinicalTrials.gov and refreshed daily.
Looking for a specific location? Browse trials by city and state.